Navigation Links
CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
Date:2/17/2011

LA JOLLA, Calif., Feb. 17, 2011 /PRNewswire/ -- CalciMedica, a biotechnology company developing small molecules to treat inflammatory and autoimmune diseases, today announced that it has dosed the first cohort in a Phase 1 clinical trial of CM2489. CM2489 is a first-in-class calcium-release activated calcium (CRAC) channel inhibitor being studied as a once-daily oral therapeutic for patients with moderate-to-severe plaque psoriasis.  In addition, the company announced that this milestone has triggered an additional $6 million tranche of financing from all existing investors, which include Sanderling Ventures, SR One and Biogen Idec New Ventures. The current financing will enable CalciMedica to complete its ongoing Phase 1 clinical trial by third quarter 2011.  

The randomized, placebo-controlled, blinded, single-ascending dose study is being conducted at a single site in the US under an Investigational New Drug (IND) application recently allowed by the FDA and will enroll 48 healthy volunteers through multiple cohorts. The goal of the study is to determine the safety, tolerability and pharmacokinetic profile of CM2489 in humans and to select doses for investigation in subsequent studies.

The CRAC channel activates a signaling pathway that is essential for the adaptive immune response in T cells. The therapeutic value of inhibiting this pathway has been established by calcineurin inhibitors, a class of immunosuppressants that work downstream from the CRAC channel.

"CM2489 is the first CRAC channel inhibitor, or CCI, to be tested in humans. CCIs have the potential to be safe and effective drugs to treat multiple chronic inflammatory and autoimmune diseases," said Gonul Velicelebi, Ph.D., president and CEO of CalciMedica. "We are targeting psoriasis as our first proof-of-concept indication and are considering rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, asthma, and multiple sclerosis for our follow-on indications."

"CRAC channels have been a drug target sought by the pharmaceutical industry for many years. These channels and the discovery of selective inhibitors that can safely modulate the immune system have been elusive," said Peter McWilliams, Ph.D., chairman of the CalciMedica board of directors and managing director at Sanderling Ventures.  "The team at CalciMedica has done a phenomenal job of identifying the channel components, discovering small molecules that inhibit the channel and bringing this pioneering approach into the clinic."

About CalciMedica

CalciMedica, a privately-held small molecule discovery and development company, has a portfolio of first-in-class drug candidates that inhibit the calcium-release activated calcium (CRAC) channel and that have the potential to treat chronic inflammatory and autoimmune diseases. The company's lead drug candidate, CM2489, is under development for the treatment of moderate-to-severe plaque psoriasis. The company has exclusive intellectual property rights to STIM and Orai proteins that constitute the CRAC channel as well as the novel compounds that inhibit the CRAC channel activity. CalciMedica's investors are Sanderling Ventures, SR One and Biogen Idec New Ventures.  For more information, visit www.calcimedica.com.


'/>"/>
SOURCE CalciMedica
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CalciMedica Appoints Evelyn Graham to its Board of Directors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a ... Executive Officer, Bill Welch , will be presenting ... at 9:00 AM EDT at the Essex House in ... and Chief Scientific Officer, Mark Erlander , Ph.D., ... the conference.   The presentation will be webcast ...
(Date:3/27/2017)... 27, 2017 Neurotrope, Inc. (OTCQB: NTRP),  ... neurodegenerative diseases, including Alzheimer,s disease, today announced that ... list the Company,s common stock on the NASDAQ ... Stock Market, a unit of the NASDAQ OMX ... the Opening Bell at the NASDAQ MarketSite in ...
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... 2017 Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... , today announced that its board of directors has amended ... plan from March 27, 2017 to March 27, 2018. The amendment was ... Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a China ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
(Date:3/6/2017)... 2017 Mintigo , the leader ... Predictive Sales Coach TM , its new artificial ... into Salesforce. This unique AI application will allow ... with deep knowledge of their customers and prospects ... Predictive Sales Coach extends Mintigo,s existing customer success ...
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
Breaking Biology News(10 mins):